• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[拉丁美洲糖尿病的成本:来自墨西哥的证据]

[The cost of diabetes in Latin America: evidence from Mexico].

作者信息

Arredondo Armando, De Icaza Esteban

机构信息

Instituto Nacional de Salud Pública, Av Universidad # 655, Cuernavaca Mor, México.

出版信息

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S85-8. doi: 10.1016/j.jval.2011.05.022.

DOI:10.1016/j.jval.2011.05.022
PMID:21839907
Abstract

UNLABELLED

The main objective was to identify economic burden from epidemiological changes and expected demand for health care services for diabetes in México. The cost evaluation method to estimate direct and indirect costs was based on instrumentation and consensus techniques. To estimate the epidemiological changes for 2009-2011, three probabilistic models were constructed according to the Box-Jenkins technique. Comparing the economic impact in 2009 versus 2011 (p< 0.05), there is a 33% increase in financial requirements. The total amount for diabetes in 2010 (US dollars) will be $778,427,475. It includes $343,226,541 in direct costs and $435,200,934 in indirect costs. The total direct costs expected are: $40,787,547 for the Ministry of Health (SSA), serving to uninsured population; $113,664,454 for insured population (Mexican Institute for Social Security-IMSS-, and Institute for Social Security and Services for State Workers-ISSSTE-); $178,477,754 to users; and $10,296,786 to Private Health Insurance (PHI).

CONCLUSIONS

If the risk factors and the different health care models remain as they are currently in the institutions analyzed, the financial consequences would be of major impact for the pockets of the users, following in order of importance, social security institutions and finally Ministry of Health. Allocate more resources to promotion and prevention of diabetes will decrease the cost increase by decreasing the demand for treatment of complications.

摘要

未标注

主要目标是确定墨西哥糖尿病流行病学变化带来的经济负担以及对医疗保健服务的预期需求。估算直接和间接成本的成本评估方法基于工具法和共识技术。为估算2009 - 2011年的流行病学变化,根据博克斯 - 詹金斯技术构建了三个概率模型。比较2009年与2011年的经济影响(p < 0.05),资金需求增长了33%。2010年糖尿病的总成本(美元)将达到778,427,475美元。其中包括343,226,541美元的直接成本和435,200,934美元的间接成本。预计的直接成本总额为:卫生部(SSA)为未参保人群提供服务的费用为40,787,547美元;为参保人群(墨西哥社会保障局 - IMSS - 以及国家工作人员社会保障和服务局 - ISSSTE - )提供服务的费用为113,664,454美元;用户承担的费用为178,477,754美元;私人医疗保险(PHI)承担的费用为10,296,786美元。

结论

如果所分析机构中的风险因素和不同医疗保健模式保持现状,那么经济后果将对用户的钱包产生重大影响,其次按重要性依次影响社会保障机构,最后是卫生部。为糖尿病的推广和预防分配更多资源将通过减少并发症治疗需求来降低成本增长。

相似文献

1
[The cost of diabetes in Latin America: evidence from Mexico].[拉丁美洲糖尿病的成本:来自墨西哥的证据]
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S85-8. doi: 10.1016/j.jval.2011.05.022.
2
[Financial requirements for health services demands for diabetes and hypertension in Mexico: 2001-2003].[墨西哥糖尿病和高血压医疗服务需求的财务要求:2001 - 2003年]
Rev Invest Clin. 2001 Sep-Oct;53(5):422-9.
3
Health care costs and financial consequences of epidemiological changes in chronic diseases in Latin America: evidence from Mexico.拉丁美洲慢性病流行变化的医疗保健成本及财务后果:来自墨西哥的证据。
Public Health. 2005 Aug;119(8):711-20. doi: 10.1016/j.puhe.2005.01.009.
4
Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case.中等收入国家糖尿病流行状况变化的经济后果:以墨西哥为例。
Diabetes Care. 2004 Jan;27(1):104-9. doi: 10.2337/diacare.27.1.104.
5
Health disparities from economic burden of diabetes in middle-income countries: evidence from México.中低收入国家糖尿病经济负担导致的健康差距:来自墨西哥的证据。
PLoS One. 2013 Jul 12;8(7):e68443. doi: 10.1371/journal.pone.0068443. Print 2013.
6
Challenges on the epidemiological and economic burden of diabetes and hypertension in Mexico.墨西哥糖尿病和高血压的流行病学及经济负担面临的挑战。
Rev Saude Publica. 2018;52:23. doi: 10.11606/s1518-8787.2018052000293. Epub 2018 Feb 26.
7
Costs and epidemiological changes of chronic diseases: implications and challenges for health systems.慢性病的成本与流行病学变化:对卫生系统的影响与挑战
PLoS One. 2015 Mar 17;10(3):e0118611. doi: 10.1371/journal.pone.0118611. eCollection 2015.
8
Epidemiologic changes and economic burden of hypertension in Latin America: evidence from Mexico.拉丁美洲高血压的流行病学变化与经济负担:来自墨西哥的证据
Am J Hypertens. 2006 Jun;19(6):553-9. doi: 10.1016/j.amjhyper.2005.10.028.
9
Epidemiological changes and financial consequences of hypertension in Latin America: implications for the health system and patients in Mexico.拉丁美洲高血压的流行病学变化及其经济后果:对墨西哥卫生系统和患者的影响。
Cad Saude Publica. 2012 Mar;28(3):497-502. doi: 10.1590/s0102-311x2012000300010.
10
Epidemiological and financial indicators of hypertension in older adults in Mexico: challenges for health planning and management in Latin America.墨西哥老年人高血压的流行病学和财务指标:拉丁美洲卫生规划与管理面临的挑战
Int J Health Plann Manage. 2017 Apr;32(2):e121-e136. doi: 10.1002/hpm.2362. Epub 2016 May 30.

引用本文的文献

1
A comparison of rural-urban differences in out-of-pocket expenses among older Mexicans with diabetes.农村-城市老年人糖尿病自付费用差异比较。
Front Public Health. 2022 Oct 21;10:1025159. doi: 10.3389/fpubh.2022.1025159. eCollection 2022.
2
Economic evaluation of a novel community-based diabetes care model in rural Mexico: a cost and cost-effectiveness study.墨西哥农村地区一种新型社区糖尿病护理模式的经济评估:一项成本与成本效益研究。
BMJ Open. 2021 Apr 7;11(4):e046826. doi: 10.1136/bmjopen-2020-046826.
3
Analysis of influencing factors of economic burden and medical service utilization of diabetic patients in China.
中国糖尿病患者经济负担和医疗服务利用的影响因素分析。
PLoS One. 2020 Oct 30;15(10):e0239844. doi: 10.1371/journal.pone.0239844. eCollection 2020.
4
Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus.2 型糖尿病患者药物治疗增强策略的成本效益分析。
BMJ Open Diabetes Res Care. 2019 Jul 16;7(1):e000647. doi: 10.1136/bmjdrc-2018-000647. eCollection 2019.
5
Early identification of peripheral neuropathy based on sudomotor dysfunction in Mexican patients with type 2 diabetes.基于汗腺功能障碍对墨西哥2型糖尿病患者周围神经病变的早期识别。
BMC Neurol. 2019 May 31;19(1):109. doi: 10.1186/s12883-019-1332-4.
6
Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes.血脂异常:拉丁美洲2型糖尿病患者未经治疗的代谢功能障碍。阿雷泰乌斯研究结果。
J Clin Transl Endocrinol. 2019 Jan 25;15:76-80. doi: 10.1016/j.jcte.2019.01.002. eCollection 2019 Mar.
7
Vanadyl Sulfate Effects on Systemic Profiles of Metabolic Syndrome in Old Rats with Fructose-Induced Obesity.硫酸氧钒对果糖诱导肥胖老龄大鼠代谢综合征全身特征的影响。
Int J Endocrinol. 2018 Dec 25;2018:5257216. doi: 10.1155/2018/5257216. eCollection 2018.
8
Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.影响墨西哥2型糖尿病患者药物反应的基因型和表型因素
Front Pharmacol. 2018 Apr 6;9:320. doi: 10.3389/fphar.2018.00320. eCollection 2018.
9
Naked-Eye Detection of Glucose in Saliva with Bienzymatic Paper-Based Sensor.双酶生物纸基传感器裸眼检测唾液中的葡萄糖
Sensors (Basel). 2018 Apr 3;18(4):1071. doi: 10.3390/s18041071.
10
The Evaluation of a Low-Cost Colorimeter for Glucose Detection in Salivary Samples.低成本比色计用于唾液样本中葡萄糖检测的评估。
Sensors (Basel). 2017 Nov 1;17(11):2495. doi: 10.3390/s17112495.